SRR29022842
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.510
- MYOGENESIS+0.490
- HEDGEHOG_SIGNALING+0.410
- ANGIOGENESIS+0.380
- FATTY_ACID_METABOLISM+0.360
- BILE_ACID_METABOLISM+0.350
- COAGULATION+0.340
- OXIDATIVE_PHOSPHORYLATION+0.330
- XENOBIOTIC_METABOLISM+0.320
- NOTCH_SIGNALING+0.280
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.590
- MYC_TARGETS_V1-0.550
- MYC_TARGETS_V2-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.470
- PROTEIN_SECRETION-0.420
- MTORC1_SIGNALING-0.410
- ANDROGEN_RESPONSE-0.330
- MITOTIC_SPINDLE-0.280
- PI3K_AKT_MTOR_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_14_0175_A4_S56 | — | A | 0.845 |
| 2 | MBCProject_7544_T2_RNA | — | A | 0.820 |
| 3 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.817 |
| 4 | SRR655435 | GTEX | — | 0.816 |
| 5 | SRR10899996 | — | — | 0.815 |
| 6 | TCGA-BH-A0BM-01A-11R-A056-07 | — | A | 0.806 |
| 7 | AUR-AER6-TTM6-A-1-1-R-A742-41 | — | C | 0.805 |
| 8 | SRR35579814 | — | A | 0.790 |
| 9 | TCGA-E2-A1IF-01A-11R-A144-07 | — | A | 0.789 |
| 10 | SRR1448162 | GTEX | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.510 | Inavolisib | — uncovered |
| MYOGENESIS | 0.490 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |